Checkpoint Therapeutics (CKPT) Earning Somewhat Positive Press Coverage, Accern Reports
Headlines about Checkpoint Therapeutics (NASDAQ:CKPT) have been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.8084943045061 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Checkpoint Therapeutics (NASDAQ:CKPT) opened at $4.66 on Tuesday. Checkpoint Therapeutics has a 52-week low of $4.61 and a 52-week high of $15.00.
COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/11/14/checkpoint-therapeutics-ckpt-earning-somewhat-positive-press-coverage-accern-reports.html.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
Receive News & Stock Ratings for Checkpoint Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics Inc. and related stocks with our FREE daily email newsletter.